Telix Pharmaceuticals Limited
Price Action
Technical Summary
CONSOLIDATINGTelix Pharmaceuticals Limited is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is leading (RS Rating: 83), indicating clear outperformance against the broad market. Earnings contraction of 131% provides fundamental context to the price action. Investors should exercise caution due to high volatility (58% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $10.71 | -0.44% | BELOW |
| 50 SMA | $9.31 | +14.53% | ABOVE |
| 100 SMA | $8.40 | +26.86% | ABOVE |
| 150 SMA | $8.94 | +19.22% | ABOVE |
| 200 SMA | $9.47 | +12.52% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is TLX in an uptrend right now?
TLX has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is TLX overbought or oversold?
TLX's RSI (14) is 65. The stock is in neutral territory, neither overbought nor oversold.
Is TLX outperforming the market?
TLX has a Relative Strength (RS) Rating of 83 out of 99. Yes, TLX is a market leader, outperforming 83% of all stocks over the past 12 months.
Where is TLX in its 52-week range?
TLX is trading at $10.66, which is 58% of its 52-week high ($18.49) and 36% above its 52-week low ($6.30).
How volatile is TLX?
TLX has a Beta of 0.89 and 52-week volatility of 58%. It's less volatile than the S&P 500 - generally more stable.